Hypofractionated radiotherapy and concomitant temozolomide for high-grade glial tumors in elderly patients Yüksek gradli gliomu olan yaşli hastalarda eş zamanli temozolamid ve hipofraksiyone radyoterapi
Turk Geriatri Dergisi, cilt.22, sa.1, ss.32-37, 2019 (SCI-Expanded, SSCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 22 Sayı: 1
- Basım Tarihi: 2019
- Doi Numarası: 10.31086/tjgeri.2019150570
- Dergi Adı: Turk Geriatri Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.32-37
- Anahtar Kelimeler: Aged, Glioblastoma, Astrocytoma, Radiation Dose Hypofractionation, Radiotherapy
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Glioblastoma is the most common primary tumor in adults and age is a poor prognostic factor. Its main treatment is surgical removal. After surgery, radiotherapy is the mainstay treatment for glioblastoma. The aim of this study was to evaluate the survival and toxicity of short-course radiotherapy (40 Gy in 15 fractions) and temozolomide. Materials and Method: A total of 22 patients over 65 years received hypofractionated radiotherapy (40 Gy in 15 fractions) and temozolomide (75 mg/m2/day). Results: No grade 3 and 4 leukopenia or thrombocytopenia occurred among the patients. The median survival for patients with grade IV disease (including gliosarcoma) was 7 months [95% confidence interval (CI), 3.0-10.9] and that of patients with grade III disease was 2 months (95% CI, 0-35.6). There was no need to stop or delay the treatment. Conclusion: Standard and short-course radiotherapy and temozolomide were found to be equally effective to prevent disease progression and salvage treatment. Notably, elderly patients find it difficult to visit a hospital everyday. Moreover, long-term therapies are financially and physically burdensome for them. Besides, comorbidities are seen often in the elderly.